Biotech Investment Analyst, Drug Asset & Company Assessment [Remote]

Lead expert human evaluation of drug assets and the companies developing them by designing and testing investment-style rubrics, then applying those frameworks to produce end-to-end asset and company assessments that inform commercial and investment judgments.

• Create and critique structured rubrics that analyze commercial drugs and drug-development programs.
• Produce overall company and asset assessments, covering mechanism of action, clinical data interpretation, competitive position, and key value drivers.
• Evaluate the strength of investment-style theses, and flag weak, overconfident, or missing assumptions.
• Apply your assessments across the pilot set of companies, approximately 5 to 10 companies.

• US-based biotech or healthcare investment analyst, ideally with a specialist-fund background.
• Minimum 5 years experience evaluating biotech or pharmaceutical companies or assets.
• Demonstrated familiarity with biotech and pharma development programs, clinical data, and commercial dynamics.
• Ability to assess a drug asset and the company behind it end-to-end, including mechanism, clinical evidence, competition, and value drivers.
• Deep US-market experience, or residency in the United States.

• Engagement type, hourly paid pilot.
• Estimated commitment, approximately 10 to 20 hours total over a 1 to 2 weeks pilot period.
• Work is remote, candidates must be US-based or have deep US-market experience.
• Assessment tasks will cover a small portfolio, roughly 5 to 10 companies during the pilot.
• Strong contributors may be invited to recurring engagements as work scales.

• $120 to $200 per hour.

• Must be US-based, or have demonstrable deep US-market experience.
• Target candidate profile, a biotech or healthcare investment analyst with a specialist-fund background and at least 5 years relevant experience.